Precigen Inc PGEN

NAS: PGEN | ISIN: US74017N1054   16:13
1,389 USD (+0,67%)
(+0,67%)   16:13
Grafiek Precigen Inc Grafiek Precigen Inc

Precigen Inc in het nieuws

14 mei 2024 · Precigen Reports First Quarter 2024 Financial Results and Business Updates · Persbericht

8 mei 2024 · Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting · Persbericht

24 april 2024 · Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting · Persbericht

24 april 2024 · Actym Therapeutics Appoints Thomas Smart as CEO · Persbericht

28 maart 2024 · Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th · Persbericht

19 maart 2024 · Precigen Reports Full Year 2023 Financial Results and Business Updates · Persbericht

12 maart 2024 · Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis · Persbericht

5 maart 2024 · Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th · Persbericht

6 februari 2024 · Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

16 januari 2024 · Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission · Persbericht

Profiel Precigen Inc

Biotechnologie
Gezondheidstechnologie

Website: www.dna.com

Hoofdzetel: Germantown, Maryland vlag Verenigde Staten

CEO: Helen Sabzevari

Werknemers: 106

Aandelen Precigen Inc

Beurswaarde: 348,34 miljoen USD

Effecten: 252,42 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 2,09

Mijn selecties